STAAR Surgical Company Common Stock (STAA)
Stock · NASDAQ · Health Care
$21.27as of 10/16/2026
Price chart
STAA Signal Track Record
How signals performed across all stocks →What STAA's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 39 | -3.5% | 41% | September 4, 2026 |
| Bollinger Band Breakdown | 22 | -2.6% | 41% | September 17, 2026 |
| Bollinger Band Breakout | 19 | +1.1% | 58% | June 25, 2026 |
| 200-Day Moving Average TouchActive now | 15 | -8.3% | 27% | September 8, 2026 |
| Any 20-session window (baseline) | -3.7% | 40% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About STAA
STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, and sells phakic implantable lenses for the eye and accessory delivery systems to deliver the lenses into the eye. The company offers implantable collamer lens product family (ICLs) comprising EVO ICL, EVO+ ICL, EVO Visian ICL, and EVO Viva ICL for use in refractive surgery for the treatment of visual disorders, such as myopia, h…
- Sector
- Health Care
- Industry
- Ophthalmic Goods
- Employees
- 921
- Website
- www.staar.com/
Fundamentals
- 1-day range
- $21.24$22.16
- Market cap
- $1.15B
- P/E (trailing)
- 280.68
- P/E (forward)
- 19.33
- EPS (trailing)
- $0.07
- Dividend yield
- —
- Beta
- 1.22
- Avg. volume
- 1.00M
How STAAR Surgical Company Common Stock Makes Money
Where the revenue actually goes — FY2025 annual results
Source: 10-K filed Mar 3, 2026 · via SEC EDGAR / Finnhub
Forecasts
9 analyst ratings
STAAR Surgical Company Common Stock Competitors
Chosen by industry and closest market cap.
- STAASTAAR Surgical Company Common Stock$21.27▼ 4.45%Market cap $1.15BP/E 280.68$15.59$35.87
- EYENational Vision Holdings Inc. Common Stock$17.43▼ 1.30%Market cap $1.80BP/E 27.65$14.75$30.02
- RXSTRxSight Inc. Common Stock$4.51▼ 3.43%Market cap $251.69MP/E —$4.4$13.22
- LUCYInnovative Eyewear Inc. Common Stock$0.79▼ 6.29%Market cap $6.19MP/E —$0.65$2.05
- LUCYWInnovative Eyewear Inc. Series A Warrants 8/16/27$0.0251▼ 10.36%Market cap $556.8KP/E —$0.0251$0.152
- WRBYWarby Parker Inc. Class A Common Stock$23.34▼ 5.08%Market cap $3.31BP/E 365.43$14.96$31
- BLCOBausch + Lomb Corporation Common Shares$16.49▼ 1.02%Market cap $5.84BP/E —$14.39$18.92
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| STAA STAAR Surgical Company Common Stock | $1.15B | 280.68 | $21.27 | ▼ 4.45% | $15.59$35.87 |
| EYE National Vision Holdings Inc. Common Stock | $1.80B | 27.65 | $17.43 | ▼ 1.30% | $14.75$30.02 |
| RXST RxSight Inc. Common Stock | $251.69M | — | $4.51 | ▼ 3.43% | $4.4$13.22 |
| LUCY Innovative Eyewear Inc. Common Stock | $6.19M | — | $0.79 | ▼ 6.29% | $0.65$2.05 |
| LUCYW Innovative Eyewear Inc. Series A Warrants 8/16/27 | $556.8K | — | $0.0251 | ▼ 10.36% | $0.0251$0.152 |
| WRBY Warby Parker Inc. Class A Common Stock | $3.31B | 365.43 | $23.34 | ▼ 5.08% | $14.96$31 |
| BLCO Bausch + Lomb Corporation Common Shares | $5.84B | — | $16.49 | ▼ 1.02% | $14.39$18.92 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- STAAR Surgical Names Andrew Pilon as Vice President of Business DevelopmentYahoo · 10/8/2026
- Winners And Losers Of Q2: STAAR Surgical (NASDAQ:STAA) Vs The Rest Of The Medical Devices & Supplies - Specialty StocksYahoo · 10/8/2026
- STAAR Surgical: A Recovery Story Priced As GrowthSeekingAlpha · 10/1/2026
- Why Staar Surgical Zoomed Almost 8% Higher on TuesdayYahoo · 9/29/2026
- STAAR Surgical (STAA) Shares Skyrocket, What You Need To KnowYahoo · 9/29/2026
- STAAR Surgical Analyst Turns Bullish On Potential For ‘Meaningful’ Street Upsidebenzinga · 9/29/2026
- STAAR Surgical jumps on Stifel upgrade citing China growth potentialYahoo · 9/29/2026
- Here Are Tuesday’s Top Wall Street Analyst Research Calls: AutoZone, Baker Hughes, FS KKR Capital, Kroger, Netflix, PepsiCo, Ryder Systems, SpaceX, Warner Bros. Discovery, and MoreYahoo · 9/29/2026
- STAAR Surgical Analyst Turns Bullish On Potential For ‘Meaningful’ Street UpsideBenzinga · 9/29/2026
Insider Activity
Insider Actions →- Warren Foust · August 14, 2026 · Option Exercise3.7K
- Warren Foust · August 14, 2026 · Option Exercise7.3K
- Warren Foust · August 14, 2026 · Grant123.7K
- Warren Foust · August 14, 2026 · Grant131.8K
- Warren Foust · August 14, 2026 · Grant38.0K
- Warren Foust · August 14, 2026 · Grant40.5K
- Warren Foust · August 14, 2026 · Grant22.5K
- Warren Foust · August 14, 2026 · Tax Withholding1.9K @ $26.18
- Warren Foust · August 14, 2026 · Tax Withholding3.7K @ $26.18
- Magda Michna · August 14, 2026 · Option Exercise1.1K @ $26.18
- Magda Michna · August 14, 2026 · Option Exercise5.5K
- Magda Michna · August 14, 2026 · Tax Withholding559 @ $26.18
- Magda Michna · August 14, 2026 · Tax Withholding2.8K @ $26.18
- Deborah J. Andrews · August 14, 2026 · Option Exercise5.2K
- Deborah J. Andrews · August 14, 2026 · Grant29.2K
Institutional Ownership
March 31, 2026
- Total shares held
- 52.29M
- Total value held
- $968.72M
- Institutional holders
- 181
- Unknown16.12M
- Unknown6.67M
- Unknown3.26M
- Unknown2.44M
- Unknown1.83M
- Unknown1.69M
- Unknown1.60M
- Unknown1.50M
- Unknown1.27M
- Unknown1.07M
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 14, 2026
STAAR Surgical Names New VP, Faces High Valuation Questions
STAAR Surgical appointed Andrew Pilon as Vice President of Business Development. Recent articles discuss whether the stock is undervalued or risky, noting its high trailing P/E of 283.5. The stock is currently trading near a key support level, with analyst targets ranging from $19.00 to $37.00.
STAAR Surgical Names New VP, Faces High Valuation Questions. STAAR Surgical appointed Andrew Pilon as Vice President of Business Development. Recent articles discuss whether the stock is undervalued or risky, noting its high trailing P/E of 283.5. The stock is currently trading near a key support level, with analyst targets ranging from $19.00 to $37.00.